Ibandronate: Once-monthly and intravenous dosing options for osteoporosis treatment

Women's Health

Volumn 2, Issue 3, 2006, Pages 341-349

  Emkey, Ronald ^a  

^a RADIANT RESEARCH   (United States)

Author keywords

Bisphosphonate; Bone; Bone remodeling; Bone turnover; Ibandronate; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K INHIBITOR; ETIDRONIC ACID; FOSAMAX PLUS D; IBANDRONIC ACID; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BEHAVIOR CHANGE; BONE DENSITY; BONE DISEASE; BONE MASS; BONE METASTASIS; BONE NECROSIS; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; DIET RESTRICTION; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS ULCER; EUROPE; EXERCISE; FEMALE; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; INHIBITION KINETICS; LIFESTYLE; MEDICAL DECISION MAKING; MORPHOMETRICS; MYELOMA; NORTH AMERICA; OSTEOCLAST; OSTEOPOROSIS; PAGET BONE DISEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT POSITIONING; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; STOMACH ULCER; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 33646804556     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.3.341     Document Type: Article

References (38)

1. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. National Osteoporosis Foundation, Washington, DC, USA (2002).
2. Manolagas SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115-137 (2000).
3. World Health Organization: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ. Tech. Rep. Ser. 843, 1-129 (1994).
4. Chesnut CH III, Skag A, Christiansen C et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19, 1241-1249 (2004).
5. Harris ST, Watts NB, Genant HK et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282, 1344-1352 (1999).
6. Cummings SR, Black DM, Thompson DE et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280, 2077-2082 (1998).
7. Cramer J, Amonkar M, Hebborn A, Altman R: Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr. Med. Res. Opin. 21, 1453-1460 (2005).
8. Recker RR, Gallagher R, MacCosbe PE: Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin. Proc. 80, 856-861 (2005).
9. Rogers MJ: New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9, 2643-2658 (2003).
10. Nancollas GH, Tang R, Phipps RJ etal.: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2006) (Epub ahead of print).
11. van Beek E, Hoekstra M, van de Ruit M, Lowik C, Papapoulos S: Structural requirements for bisphosphonate actions in vitro. J. Bone Miner. Res. 9, 1875-1882 (1994).
12. Fleisch H: Bisphosphonates: mechanisms of action. Endocr. Rev. 19, 80-100 (1998).
13. Muhibauer RC, Bauss F, Schenk R et al.: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6, 1003-1011 (1991).
14. Miller PD, McClung MR, Macovei L et al.: Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J. Bone Miner. Res. 20, 1315-1322 (2005).
15. Reginster JY, Wilson KM, Dumont E, Bonvoisin B, Barrett J: Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J. Clin. Endocrinol. Metab. 90(50), 5018-5024 (2005).
16. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13, 581-589 (1998).
17. Lehmann HJ, Mouritzen U, Christgau S, Cloos PA, Christiansen C: Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann. Rheum. Dis. 61, 530-533 (2002).
18. Delmas PD, Recker RR, Chesnut CH III et al: Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos. Int. 15, 792-798 (2004).
19. Christiansen C, Tanko, LB, Warming L et al.: Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos. Int. 14, 609-613 (2003).
20. Lewiecki M, Zaidi M, Drezner M, Recknor C: Intermittent intravenous ibandronate injections are at least as effective as daily oral ibandronate: 1-Year DIVA results. Menopause 12, 802 (2005).
21. Delmas PD, Adami S, Strugala C et al.: Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year results from the DIVA study. Arthritis Rheum. (2006) (In press).
22. Recker RR, Weinstein RS, Chesnut CH III et al.: Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos. Int. 15, 231-237 (2004).
23. Reginster JY, Adami S, Lakatos P et al.: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann. Rheum. Dis (2006) (Epub ahead of print).
24. Bamias A, Kastritis C, Bamia C et al.: Osteonecrosis of the Jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 23, 8580-8587 (2005).
25. Marx RE, Sawatari Y, Fortin M, Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factorsm recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63, 1567-1575 (2005).
26. Simon J, Beusterien K, Hebborn A, Leidy N: Women with postmenopausal osteoporosis express a preference for once-monthly versus once-weekly bisphosphonate treatment. Female Patient 30, 31-36 (2005).
27. Emkey R, Koltun W, Beusterien K et al.: Patient preference for once-monthly ibandronate vesus once-weekly alendronate in a randomized, open-label, crossover trial: the Boniva Aldendronate Trial in Osteoporosis (BALTO). Curr. Med. Res. Opin. 21, 1895-1903 (2005).
28. Hadji P, Benhamou C-L, Devas V, Masanauskaite D, Barrett-Connor E: Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: results of BALTO II. Sixth European Congress on Clinical & Economic Aspects of Osteoporosis & Osteoarthritis (ECCEO). Vienna, Austria, March 15-18 (2006).
29. Black DM, Greenspan SL, Ensrud KE et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207-1215 (2003).
30. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349, 1216-1226 (2003).
31. Rittmaster RS, Bolognese M, Ettinger MP et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 85, 2129-2134 (2000).
32. Stroup GB, Lark MW, Veber DF et al.: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. 16, 1739-1746 (2001).
33. Hanada K, Furuya K, Yamamoto N et al.: Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol. Pharm. Bull. 26, 1563-1569 (2003).
34. Rosen J, Negro-Vilar A: Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J. Musculoskelet. Neuronal Interact. 2, 222-224 (2002).
35. Bekker PJ, Holloway DL, Rasmussen AS et al.: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066 (2004).
36. Pfeifer M, Minne HW: Vitamin D and Hip Fracture. Trends Endocrinol. Metab. 10, 417-420 (1999).
37. Murphy NM, Carroll P: The effect of physical activity and its interaction with nutrition on bone health. Proc. Nutr. Soc. 62, 829-838 (2003).
38. Mein AL, Briffa NK, Dhaliwal SS, Price RI: Lifestyle influences on 9-year changes in BMD in young women. J. Bone Miner. Res. 19, 1092-1098 (2004).